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Background: Vaccination remains one of the most effective approaches to prevent the spread of infectious
diseases. Immune responses to vaccination can be enhanced by inclusion of adjuvant in a vaccine. Paclitaxel
extracted from the bark of the Pacific yew tree Taxus brevifola was previously demonstrated to have adjuvant
property. Compared to paclitaxel, docetaxel is another member of taxane family, and is more soluble in water and
easier to manipulate in medication. To investigate the adjuvant effect of this compound, we measured the immune
responses induced by co-administration of a split inactivated influenza H1N1 vaccine antigen with docetaxel.
Results: When co-administered with docetaxel, lower dose antigen (equivalent to 10 ng HA) induced similar
levels of IgG and IgG isotypes as well as HI titers to those induced by higher dose antigen (equivalent to
100 ng HA). Docetaxel promoted splenocyte responses to H1N1 antigen, ConA and LPS, mRNA expressions of
cytokines (IFN-gamma, IL-12, IL-4 and IL-10) and T-bet/GATA-3 by splenocytes. The enhanced immunity was
associated with up-expressed microRNAs (miR-155, miR-150 and miR-146a) in docetaxel-stimulated RAW264.7
cells. Docetaxel promoted similar IgE level to but alum promoted significantly higher IgE level than the control.
Conclusion: Docetaxel has adjuvant effect on the influenza H1N1 vaccine by up-regulation of Th1/Th2 immune
responses. Considering its unique vaccine adjuvant property as well as the safe record as an anti-neoplastic
agent clinically used in humans during a long period, docetaxel should be further studied for its use in
influenza vaccine production.
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The current strategy for prevention of annual seasonal
influenza is primarily based on the trivalent inactivated
vaccine, which consists of split viral envelopes with the
protein hemagglutinin (HA) as the main vaccine antigen
[1,2]. Although the method has been utilized for many
years, vaccination remains one of the most effective
approaches, not only to prevent the spread of the influ-
enza virus but also to mitigate the severity of illness and
the impact of the disease [3] Since the rapid spread of
the swine-origin influenza A (H1N1) 2009 pandemic
worldwide, the rapid implementation of a vaccine has
become a global priority.* Correspondence: Songhua@zju.edu.cn
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reproduction in any medium, provided the orA previous investigation found that vaccination with re-
cent seasonal influenza vaccines provided little or no
cross-reactive antibody protection against 2009 pandemic
influenza A (H1N1) in any age groups [4]. The lack of
cross-protective immunity between the pandemic and sea-
sonal influenza virus strains highlighted the urgency of
rapid vaccine development. The present global production
capacity of trivalent seasonal influenza vaccine is about
876 million doses per year. With a world population of
more than 6.5 billion people and the probability that two
vaccine doses should be administered in a largely naive
population, it should be predicted that about 13 billion
doses of pandemic vaccine would be needed for adequate
pandemic preparedness. The yield of virus in eggs or cell
cultures is another important determinant for the amount
of vaccine doses that can be manufactured. In spite of the
WHO global pandemic influenza action plan to increase
the potential supply of pandemic influenza vaccine [5], the
production of sufficient pandemic vaccine to immunizetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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existing manufacturing capacities.
To effectively vaccinate the high-risk population
against pandemic influenza, two challenges are to pro-
duce sufficient quantities of vaccine during a short
period and to induce significant immunogenicity and
cross-protective immunity after vaccine injections [6-8].
Luckily, both purposes can be achieved by using adju-
vant to elicit a strong and broadened immune response.
Although many materials have been reported having ad-
juvant property, alum (a term for aluminum-based min-
eral salts) is the first adjuvant approved by the U.S. Food
and Drug Administration (FDA) in the influenza vac-
cines for human use. However, highly heterogeneous,
difficult to manufacture in a consistent and reproducible
manner, and a boost injection required to generate pro-
tection limited alum in influenza vaccine use [9,10]. It is
also found that certain antigens do not adsorb well onto
alum due to the presence of the same charge on the ad-
juvant and antigens [11]. MF59 is an oil-in-water emul-
sion adjuvant, which has been formulated in vaccines
licensed for human use [12]. Although adverse effects of
MF59 are rare, the events such fever, chills, malaise, my-
algia, arthralgia, nausea, headache and rash have been
found after immunization of MF59-adjuvanted vaccines
[13,14]. Therefore, searching for new vaccine adjuvants
remain an interesting topic.
Paclitaxel, a member in the taxane family, was initially
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Figure 1 Serum IgG titers elicited by inactivated H1N1 influenza virus
weeks 0 and 3 with 100 μg docetaxel, inactivated H1N1 influenza virus vac
virus vaccine (equivalent to 10 ng HA) adjuvanted with docetaxel (25, 50, 1
after the second immunization for analysis of IgG titers by indirect ELISA. V
saline-immunized mice (negative control) multiplied by a factor of 2.1 were
depicted as reciprocal end-dilutions. Significant differences with 10 ng HA
indicates that IgG titer was not detectable at the lowest dilution of serum.brevifola in early 1960s and its structure was confirmed
in 1971 [15]. At the late 1970s, paclitaxel was discovered
able to blocks mitosis and cause the death of cancer cells
by binding to and stabilizing microtubules [16,17]. In
1992, the drug was approved for the treatment of
advanced ovarian cancer, and then has been successfully
used in other solid tumors [18,19]. The drug has a safe
record in humans for almost 20 years. Based on the
TLR4 agonist activity of paclitaxel at a low dose for
stimulation of proinflammatory mediator release from
isolated macrophages, it was previously demonstrated
that paclitaxel has an adjuvant effect on the immune
responses [20,21]. When co-administrated with pacli-
taxel, OVA induced significantly higher IgG, IgG sub-
class and IgM responses in association with upregulation
of mRNA expression of T-bet/GATA-3 than when OVA
was immunized alone [21].
Docetaxel is another member of the taxane family.
Compared to paclitaxel, docetaxel is more soluble in
water, and easier to manipulate in medication. Docetaxel
has also been found to have immunomodulatory proper-
ties. Garnett et al. recently reported that intraperitoneal
injection of docetaxel after subcutaneous inoculation of
a recombinant poxviral vaccine significantly enhanced
the immune response in a mouse model [22]. Present
study was designed to investigate if co-administration of
a split inactivated influenza H1N1 vaccine antigen with
docetaxel could enhance the immune responses by
measuring serum specific antibody responses, total IgE,el (µg/dose)
**
****
50 100 200 200µg
Alum
10 ng HA 
antigen. Mice (8 animals/group) were subcutaneously injected at
cine (equivalent to 10 or 100 ng HA) or inactivated H1N1 influenza
00 or 200 μg) or alum (200 μg). Blood samples were collected 2 weeks
alues above the cut-off background level, mean value of sera from
considered positive. Values represent mean± S.D. Titers were
groups were designated as *P value< 0.05 and **P< 0.01. N.D.
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liferation as well as mRNA of cytokines and transcrip-
tion factors produced by splenocytes in Balb/c mice.
Dose-sparing effect of the influenza antigen was also
evaluated when docetaxel was administered with the
antigen.Results
Serum vaccine-specific IgG and IgG isotypes
Serum specific IgG and the IgG subclasses were measured
by an indirect ELISA to evaluate the adjuvant effect of
docetaxel on the humoral immune responses. Figure 1
shows that vaccine containing 10 ng HA (referred as
10 ng HA hereafter) induced significantly lower vaccine-
specific IgG titers than 100 ng HA (P< 0.05). However,
the IgG titer induced by 10 ng HA in combination with
docetaxel (100 or 200 μg) was 23 times higher than that
induced by the same amount of HA (P< 0.01) and similar
to the IgG titer elicited by 100 ng of HA (P> 0.05). IgG
titers were dose-dependent on the amount of docetaxel,
and reached the highest when docetaxel was at 100 and
200 μg but was not significantly increased when docetaxel
increased from 100 μg to 200 μg. Although IgG titer in
alum-adjuvanted group was significantly higher than no
adjuvanted group, it was significantly lower than that in
the group adjuvanted with 100 or 200 μg of docetaxel. As
no OD values of the sera from docetaxel-injected mice
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Figure 2 Serum specific IgG1, IgG2a, IgG2b and IgG3 levels. Mice (8 a
100 μg docetaxel, inactivated H1N1 influenza virus vaccine (equivalent to 1
(equivalent to 10 ng HA) adjuvanted with docetaxel (25, 50, 100 or 200 μg
second immunization for IgG isotype analysis by indirect ELISA. Values repr
designated as *P< 0.05 and **P< 0.01.saline-injected mice (negative controls), IgG titer was ac-
tually undetectable in docetaxel-injected group.
Figure 2 indicates that 100 ng of HA induced higher
vaccine-specific IgG1, IgG2a, IgG2b and IgG3b responses
than 10 ng of HA (P< 0.05). Supplement of docetaxel
(100 or 200 μg) but not alum in 10 ng of HA significantly
enhanced the isotypes IgG1, IgG2a, IgG2b and IgG3b
responses when compared with the group injected with
same amount of HA without adjuvant.
HI titers
To investigate the effect of docetaxel on serum HI re-
sponse, mice were immunized twice s. c. and serum HI
titers were determined. Figure 3 indicates that 10 ng of
HA induced lower HA-specific HI titer than 100 ng of
HA vaccine (P< 0.05). Co-administration of virus antigen
(equivalent to 10 ng HA) with docetaxel at the dose more
than 50 μg induced higher HI titers than the same amount
of virus antigen without adjuvant. HI titer induced by
10 ng HA antigen adjuvanted with 100 or 200 μg of doce-
taxel was similar to that induced by 100 ng of HA vaccine
alone or 10 ng of HA vaccine adjuvanted with alum.
Lymphocyte proliferative responses
Figure 4 shows the effect of docetaxel on splenocyte pro-
liferative responses to virus antigen, Con A and LPS stimu-
lation. Higher splenocyte responses to vaccine (P< 0.05),
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Figure 3 Serum HI titers. Mice (8 animals/group) were subcutaneously injected at weeks 0 and 3 with 100 μg docetaxel, inactivated H1N1
influenza virus antigen (equivalent to 10 or 100 ng HA) or inactivated H1N1 influenza virus antigen (equivalent to 10 ng HA) adjuvanted with
docetaxel (25, 50, 100 or 200 μg). Blood samples were collected 2 weeks after the second immunization for hemagglutination inhibition test.
Values represent geometrical mean titer (GMT) ± S.D. Significant differences with 10 ng HA group was designated as *P< 0.05 and **P< 0.01. N.D.
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Figure 4 Mitogen-stimulated proliferations of splenocytes. Splenocytes isolated from mice (8 animals/group) received twice subcutaneous
injections at weeks 0 and 3 of split H1N1 influenza virus antigen (equivalent to 10 and 100 ng HA) or inactivated H1N1 influenza virus antigen
(equivalent to 10 ng HA) co-administrated with docetaxel (25, 50, 100 and 200 μg) or alum (200 μg) and docetaxel administrated alone.
Splenocytes were prepared 2 weeks after the last immunization and cultured with ConA, LPS or RPMI 1640. Splenocyte proliferation was
measured by the MTT method as described in the text, and is shown as a stimulation index (SI). Values represent mean± S.D. Significant
differences with 10 ng HA groups were designated as *P< 0.05 and **P< 0.01.
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nized with vaccine containing 10 ng HA only. Supplement
of docetaxel and alum in 10 ng HA vaccine enhanced sple-
nocyte proliferative responses to the mitogens and vaccine.
Significantly higher splenocyte responses to vaccine, ConA
and LPS were detected in groups adjuvanted with doce-
taxel (100 and 200 μg) than in the control (immunized
with vaccine containing 10 ng HA). Splenocyte prolifera-
tive responses to mitogen and vaccine stimulation were
numerically higher in mice injected with 10 ng HA plus
100 or 200 μg of docetaxel than in mice injected with
100 ng HA alone. Proliferative responses to mitogens and
HA of the splenocytes from mice injected with docetaxel
only were at the same level as those from the mice injected
with saline.Serum total IgE
Figure 5 shows that serum total IgE level in docetaxel-
vaccine group was significantly lower than in alum-
vaccine group (P< 0.05), but similar to the control
(P> 0.05).Cytokines mRNA expression
To investigate the effect of docetaxel and alum on cyto-
kines mRNA expression, RNA was isolated from mouse
splenocytes 2 weeks after inoculation and cytokines
mRNA was quantified by real-time PCR (Figure 6A).
When adjuvant was added, a remarkable change in the
cytokine profile was observed. Alum (200 μg) and doce-
taxel (100 μg) induced different changes in the cyto-
kines. Docetaxel + 10 ng HA induced higher mRNA
expression of all cytokines than the control (10 ng HA
alone) (P< 0.05), while alum+ 10 ng HA triggered sig-






















Figure 5 Serum total IgE level in immunized mice. Mice (8 animals/gro
split H1N1 influenza virus antigen (containing 10 ng HA), or 10 ng HA plus
after the second immunization for analysis of total IgE. Significant differencmRNA expression than the control (10 ng HA alone)
(P< 0.05).
Docetaxel and alum induced different patterns of T-
bet and GATA-3 mRNA expression as shown in
Figure 6B. Docetaxel + 10 ng HA induced significantly
higher both T-bet and GATA-3 mRNA expression than
the control without adjuvant (P< 0.05); alum+10 ng
HA induced significantly higher GATA-3 (P< 0.05) than
the docetaxel group but similar T-bet mRNA expression
to the control (P> 0.05 alone).
MicroRNAs expressed by macrophages stimulated in vitro
by docetaxel
When murine macrophages were incubated with doce-
taxel at 0.8 μg/ml for 1 h, only miR-146a expression was
significantly increased in comparison with the control
(Figure 7D); 3 hours later, the expression of miR-155,
miR-150 and miR-146a was significantly increased
(Figure 7B, C, D) while miR-181a and miR-125b had no
significant changes (Figure 7A, E).
Discussion
Adjuvant properties of docetaxel have been demon-
strated for inactivated H1N1 influenza vaccine in a
mouse model in the present study. Co-administration
of docetaxel with inactivated influenza virus H1N1
induced significantly higher serum specific IgG and the
isotype responses, HI titer, splenocyte proliferation in
response to ConA, LPS and HA than when influenza
vaccine was immunized alone. In addition, significantly
increased mRNA expressions of IFN-γ, IL-12, IL-4 and
IL-10 by splenocytes in association with up-regulation
of mRNA expression of T-bet/GATA-3 were observed
in docetaxel-adjuvanted groups. Serum total IgE level in
the docetaxel adjuvanted group was significantly lower*
HA/Docetaxel HA/Alum 
roup
up) received twice subcutaneous injections at weeks 0 and 3 of saline,
100 μg docetaxel or plus 200 μg alum. The mice were bled 2 weeks
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Figure 6 Expression of cytokines and transcript factors mRNA by splenocytes. Mice (8 animals/group) received twice subcutaneous
injections at week 0 and 3 of inactivated H1N1 influenza virus antigen (equivalent to 10 ng HA) alone or with docetaxel (100 μg) or alum
(200 μg). Mice injected with saline only were used as a calibrator group. Splenocytes were prepared 2 weeks after the second immunization and
cultured with HA (1.32 μg/ml) for 10 h. mRNA expression of cytokines IFN-γ, IL-12, IL-4 and IL-10 (A) and transcript factors T-bet and Gata-3 (B)
was analyzed by real-time PCR. Results are reported as the n-fold difference relative to cytokine mRNA expression of calibrator sample. Significant
differences with 10 ng HA groups were designated as *P< 0.05 and **P< 0.01.
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and miR-146a are up-regulated in Raw 264.7 cells in re-
sponse to docetaxel.
The mouse model has been used to study the immunity
of a host against influenza infection for long time. For ex-
ample, Cox et al. immunized mice with a split influenza
virus vaccine, and observed that the inhibition of viral rep-
lication by immunization correlates high influenza specific
serum IgG concentrations [23]. Caillet et al. immunized
Balb/c mice with a H1N1 influenza vaccine using oil-in-
water emulsion AF03 as an adjuvant, and found that the
mice receiving AF03-adjuvanted vaccine had antigen-
specific antibody titers 3- to 10-fold higher than that in
animals administered antigen alone [24]. The antibody re-
sponse elicited by antigen is dose-dependent. Caillet et al.
reported that 0.3 μg influenza vaccine antigen induced
lower HI tiers than 3 μg antigen in mice [24]. Similarly, wefound that 10 ng HA antigen elicited significantly lower
serum IgG and HI titers or the IgG isotypes than 100 ng
HA antigen. However, supplement of docetaxel (50 to
200 μg) in 10 ng HA antigen significantly amplified IgG
and HI titers, which were similar to the titers elicited by
100 ng HA when docetaxel was added at 100 or 200 μg as
indicated in Figures 1 and 3, suggesting that the same level
of the immune responses could be induced by smaller dose
of antigen if docetaxel is used as an adjuvant in the produc-
tion of vaccines. Garnett et al. significantly enhanced the
immune response to a recombinant poxviral vaccine by in-
jection of docetaxel at 500 μg [22]. In this study, antibody
titers had no long significant changes when docetaxel was
increased from 100 to 200 μg per dose.
IgG is the most plentiful immunoglobulin in the
serum, and provides the considerable protection against



























































































































Figure 7 MicroRNAs in murine macrophages (RAW264.7 cells).
Macrophages were cultured with saline (empty bars) or 0.8 μg/ml of
docetaxel (dark bars) for the indicated lengths of time. Real-time
PCR was performed to determination of miR-181a (A), miR-155 (B),
miR-150 (C), miR-146a (D) and miR-125b (E) as described in
methods. Data are presented as copies ± SD/cell (n = 3). Significant
differences with the control were designated as *P< 0.05 and
**P< 0.01.
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the principal immunoglobulin class of the specific anti-
bodies. This subclass switch is influenced by T-cells and
their cytokines. Data in Figure 2 indicated that docetaxel
significantly increased the production of all IgG isotypes,
which may be associated with simultaneously up-regulated
gene expression of T-bet and GATA-3 (Figure 6B), leading
to increased production of IFN-γ, IL-12, IL-4 and IL-10 by
splenocytes (Figure 6A). While alum enhanced only IgG1
(P< 0.05) but not IgG2a, IgG2b and IgG3 (P> 0.05), which
may be related to up-regulated gene expression of GATA-3,
resulting in enhanced production of Th2 type cytokines
such as IL-4 and IL-10 as shown in Figure 6A. All these
suggest that docetaxel activated both Th1 and Th2 while
alum only triggered Th2 type immune responses.
Hemagglutinin has the capacity of binding to erythro-
cytes resulting in agglutination, which can be visually
detected and thus used as assay read-out. The binding of
HA to erythrocytes is inhibited by the addition of serum
containing anti-HA antibodies. Thus, the concentration
of anti-HA antibodies can be defined as HI titer by incu-
bating serial dilutions of sera with HA antigen or whole
virus [25]. In humans, HI titer of 1:40 or higher is nor-
mally considered protective [26]. Figure 3 showed that
docetaxel increased HI titers, indicating that the protec-
tion capacity against influenza infection was increased in
the immunized animals.
The lymphocyte proliferative response depends on the
mitogen used. ConA stimulates T-cell whereas LPS sti-
mulates B cell proliferation. Increased lymphocyte prolif-
eration responses to ConA and LPS were found in
docetaxel- and alum-adjuvanted groups (Figure 4), indi-
cating that both T and B cells were activated. In order to
induce antibody production, antigen-specific B lympho-
cytes should be triggered for clonal expansion. Signifi-
cantly enhanced lymphocyte responses to H1N1 HA
antigen, paralleled the increased HA-specific IgG
responses in mice immunized with docetaxel- or alum-
adjuvanted H1N1 vaccine.
Unlike paclitaxel, docetaxel does not bind to TLR4 nor
stimulate proinflammatory cytokine responses [27]. Gar-
nett et al. recently reported that docetaxel modulated
CD4+, CD8+, CD19+, natural killer cells, and Treg popu-
lations and enhanced CD8+ functions [22]. The adjuvant
activity of docetaxel may be related to its
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broad class of small non-coding RNAs (18–25 nucleo-
tides) with crucial roles in regulation of gene expression.
Previous studies have shown that miR-155, miR-150,
miR-146a, miR-181a and miR-125b are involved in the
innate immune reactions. Stimulation of monocytes with
lipopolysaccharide (LPS) induced the expression of miR-
146 and miR-155 [28]. MiR-155 and miR-125b were
found to be up-regulated and down-regulated, respect-
ively, in Raw 264.7 macrophages in response to LPS.
The miR-150 has a dynamic expression profile during
lymphocyte development, being highly expressed in ma-
ture B cells and T cells but not in their progenitors, its
expression is then extinguished after further differenti-
ation of naive T cells into the Th1 and Th2 subsets [29].
MiR-181a has been ascribed functions in hematopoietic
differentiation and in T cell differentiation [30,31]. In
this study, miR-181a, miR-155, miR-150, miR-146a and
miR-125b were analyzed to identify microRNAs possibly
involved in responses to docetaxel stimulation (Figure 7).
Only miR-146a showed significant increase 1 hour after
stimulation of RAW264.7 cells with docetaxel
(Figure 7D). Three hours later, miR-155, miR-150 and
miR-146a expressions were enhanced (Figure 7B, C, D),
while miR-181a and miR-125b showed no significant
change (Figure 7A, E). Increased expression of miR-155
and miR-146a has also been found in our previous study
when RAW264.7 cells were stimulated with paclitaxel
[21]. These suggested that stimulation manner of doce-
taxel may be different from that of LPS.
Safety should be taken into account when seeking ad-
juvant candidates. However, the safety of many drugs
largely depends on how the drugs are used. Many drugs
are safe at a small dose while becoming toxic when they
are administered frequently at a higher dose. Compared
to other potential vaccine adjuvant candidates reported
in literatures, the toxicity of docetaxel is transparent as
it has been clinically used for almost 20 years. When
docetaxel was used as an antineoplastic agent, the side-
effects such as short-lasting neutropenia and hypersensi-
tive reactions were reported [32]. The other toxicities
were hematopoietic (rats, mice, dogs and monkeys),
gastrointestinal (dogs, monkeys) and neuromotor (mice),
and are either usually mild in severity or easily treated
or prevented [33]. In our study, the suggested dose of
docetaxel for adjuvant purpose was 100 μg/mice, which
was significantly lower than that recommended for can-
cer treatment (47 mg/kg).
The adjuvant effect of aluminum salts on influenza
vaccine has been proven previously [34]. However, fre-
quent use of alum-adjuvanted vaccines could be one of
the reasons for IgE-mediated allergy due to activated
Th2 immune response [35,36]. In the present study,
alum but not docetaxel promoted the production of IgEsignificantly higher than that of mice immunized with
HA only (Figure 5). The increased serum IgE level may
be attributed to higher Th2 (IL-4, IL-10, GATA-3) and
lower Th1 (IFN-γ, IL-12, T-bet) responses in mice
injected with alum-adjuvated vaccine as indicated in
Figure 6.
Conclusions
In summary, docetaxel has an adjuvant effect on a split
influenza A H1N1 vaccine by up-regulating Th1 and
Th2 immune responses in a mouse model. When co-
administered with docetaxel, 10 ng of H1N1 virus anti-
gen (HA) induced similar level of IgG and IgG isotype
responses as well as HI titers to those induced by 100 ng
of HA. Docetaxel promoted splenocyte proliferative re-
sponse to H1N1 antigen, ConA and LPS, mRNA expres-
sions of cytokines (IL-4, IL-10, IL-12 and IFN-γ) and T-
bet/GATA-3 by splenocytes. The enhanced immune
responses may be associated with up-expressed micro-
RNAs (miR-155, miR-150 and miR-146a) as detected in
docetaxel-stimulated RAW264.7 cells. Docetaxel pro-
moted similar IgE level to but alum promoted signifi-
cantly higher IgE level than the control. Considering its
unique vaccine adjuvant property as demonstrated here
as well as the safe record clinically used in humans dur-
ing a long period, docetaxel should be further evaluated
for its use in vaccines.
Methods
Animals
Female Balb/c mice were purchased from Shanghai La-
boratory Animal Center (SLAC) Co., Ltd. (Shanghai,
China), and housed in polypropylene cages with sawdust
bedding in hygienically controlled environment. The
temperature was controlled at 24 ± 1°C and humidity at
50 ± 10%. Feed and water were supplied ad libitum.
Ethic statement
All procedures related to the animals and their care con-
formed to the internationally accepted principles as
found in the Guidelines for Keeping Experimental Ani-
mals issued by the government of China. One of the
authors (Yu Chen) received license (No. X1003003) for
management of experimental animals from the Office in
Charge of Experimental Animals of Zhejiang Province.
The Department of Veterinary Medicine has the relevant
approval to carry out animal study in general and need
not additional approval for this study.
Antigen and adjuvant
Split inactivated influenza virus NYMCX-179A (H1N1)
was kindly supplied by Zhejiang Provincial Center for
Diseases Control and Prevention, which contained
132 μg/ml of hemagglutinin (HA) determined by a
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tially as described by Wood et al. [37]. Docetaxel was
purchased from Xi’an Hao-xuan Biotechnology Co., Ltd
(Xi’an, China). Docetaxel was white powder with purity
of 99.5%. Docetaxel was dissolved in absolute ethanol,
polysorbate 80, saline (1:1:18) and sterilized by passing
through a 0.22 μm filter. The endotoxin level in the
solutions was less than 0.5 endotoxin unit (EU)/ml by a
gel-clot Limulus amebocyte lysate assay (Bath no.,
Zhanjiang A & C Biological Ltd., Zhanjiang, China).
Aluminum hydroxide Gel (Sigma, A8222) was used as
the positive control adjuvant.
Immunization
Seventy-two Balb/c mice (6 weeks of age) were randomly
distributed into nine groups with 8 mice each. All ani-
mals were subcutaneously (s.c.) immunized twice with
saline, docetaxel (100 μg), Ag (100 or 10 ng HA) or Ag
(10 ng HA) + docetaxel (25, 50, 100 or 200 μg) at 3 week
intervals, and the alum adjuvanted group as the positive
control. Two weeks after the boost, blood samples were
collected for measurement of serum HI titers using
chicken red blood cells, Ag-specific IgG titers as well as
IgG isotypes, and total IgE levels. Splenocytes were pre-
pared for determination of cellular proliferation and pro-
duction of IFN-γ, IL-12, IL-4, IL-10, T-bet and GATA-3.
All the injection solution was in the volume of 0.1 ml
per mouse.
Measurement of Vaccine-specific IgG, IgG isotypes and
total IgE
Serum samples were analyzed for measurement of
vaccine-specific IgG titer and IgG isotype responses by in-
direct enzyme-linked immunosorbent assay as previously
described by Song et al. [38]. Total IgE was measured
using a mouse IgE ELISA quantitation kit (Biolegend, Cat.
No. 432404) following the manufacturer’s instructions.
The sensitivity of the assay was 0.1 ng/ml for mouse IgE.
Serum was diluted 1:50 with 1× assay diluent.
Hemagglutination inhibition assay
Serum HI titers were determined according to the proto-
col adapted from the CDC laboratory-based influenza
surveillance manual [39].
Lymphocyte proliferation assay
Spleen collected from the immunized Balb/c mice under
aseptic conditions, in Hank’s balanced salt solution (HBSS,
Sigma), was minced and passed through a fine steel mesh
to obtain a homogeneous cell suspension. After centrifu-
gation (380× g at 4°C for 10 min), the pelleted cells were
washed three times in PBS and resuspended in complete
medium (RPMI 1640 supplemented with 0.05 mM 2-
mercaptoethanol, 100 UI/ml penicillin, 100 μg/mlstreptomycin and 10% heat inactivated FCS). Cell num-
bers were counted with a haemocytometer by trypan blue
dye exclusion technique. Cell viability exceeded 95%. Sple-
nocyte proliferation was assayed as described previously
with some modification [40]. Briefly, splenocytes were
seeded into a 96-well flat-bottom microtiter plate (Nunc)
at 5.0 × 106 cell/ml in 100 μl complete medium, thereafter
concanavalin A (Con A, final concentration 5 μg/ml), LPS
(final concentration 7.5 μg/ml), H1N1(final concentration
1.32 μg/ml) or medium were added giving a final volume
of 200 μl. The plates were incubated at 37°C in a humid
atmosphere with 5% CO2 for 2 days or 4 days. All the tests
were carried out in triplicate. The cell proliferation was
evaluated using MTT methods. Briefly, 50 μl of MTT so-
lution (2 mg/ml) were added to each well 4 h before the
end of incubation. The plates were centrifuged (1400× g,
5 min) and the untransformed MTT was removed care-
fully by pipetting. To each well 150 μl of a DMSO work-
ing solution (192 μl DMSO with 8 μl 1 N HCl) was
added, and the absorbance was evaluated in an ELISA
reader at 570 nm with a 630 nm reference after 15 min.
The stimulation index (SI) was calculated based on the
following formula:
SI ¼ the absorbance value for mitogen cultures
divided by the absorbance value for non
stimulated cultures:
Quantification of target genes by real-time PCR
Splenocytes from the H1N1-immunized Balb/c mice pre-
pared as described before were seeded into a 24-well flat-
bottom microtiter plate (Nunc) at 5 × 106 in 2 ml
complete medium, thereafter 20 μl split virus antigen
(equivalent to 2.64 ng HA) was added. The plates were
incubated at 37°C in a humid atmosphere with 5% CO2.
After 10 h treatment, cells were harvested by centrifuga-
tion (380× g at 4°C for 10 min), and washed with ice-cold
PBS, then subjected to RNA extraction. Splenocytes
(1× 107) were lysed in 1 ml of RNAisoTM Plus (Takara,
China) reagent and the total RNA was isolated according
to the manufacture’s protocol. The concentration of total
RNA was quantified by determining the optical density at
260 nm. The total RNA was used and reverse transcrip-
tion was performed by mixing 1 μg of RNA with 5 μl
iScript reagent (Bio-Rad) in a DEPC-treated tube, there-
after nuclease-free water was added to a final volume of
20 μl. The reaction condition for reverse transcription was
performed according to the manufacture’s protocol (5 min
at 25°C, 30 min at 42°C, 5 min at 85°C, hold at 4°C).
Relative quantitation of GATA-3, T-bet and cytokines
cDNA to β-actin message was conducted on ABI 7300
(PE Applied Biosystems, USA). The purpose of the
house keeping gene (β-actin) is to normalize the PCRs
for the RNA added to the reverse transcription reactions














Poly (T) adapter: 5′-GCGAGCACAGAATTAATACGACTCACTAT
AGG (T)12VN-3′ (V = A,G,C; N =A,T,G,C)
[Virginie Olive 2009]
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[41]. The PCR was performed in a dual PCR with pri-
mers and Tag-Man probes for the target gene and β-
actin cDNA in the same reaction vessel. The primers
and probes for target gene and β-actin (Table 1) were
designed using Primer Express 3.0 (PE Applied Biosys-
tems) according to the manufacturer’s directions and
each primer was located in different exons of target
genes. Probes for GATA-3, T-bet and cytokines were
detected via a 5′ labeled with reporter dye (FAM) (San-
gon Co., Ltd., Shanghai, China) and 3′ labeled with
quench dye (BHQ-1) (Sangon Co., Ltd., Shanghai,
China), while probes for β-actin were 5′ labeled with re-
porter dye (HEX) (Sangon Co., Ltd., Shanghai, China).
The PCR products were identified by DNA sequencing.
Amplification was carried out in a total volume of 20 μl
containing 2 μl of 10× PCR buffer, 2 μl of MgCl2
(25 mM), 2 μl of dNTPmix (2.5 mM), 0.4 μl of Tag DNA
polymerase (Takara, China), 2 μl of cDNA template, 2 μl
(5 μM) of each target gene and β-actin specific primers,
1 μl (5 μM) of target gene and β-actin specific probes. Re-
action conditions were the standard conditions for the
TagMan PCR (15 s denaturation at 95°C, 30 s annealing at
60°C) with 45 PCR cycles. Relative quantification between
samples was achieved by the 2-ΔΔCT method [42] andTable 1 Sequences of primer and probe for quantitative






















Probe: 5′FAM-CTGGGAAGCTGAGAGTCGCGCTCA-BHQ-1 3′calculated by software REST 2005 (gifted by Eppendorf
company), and is reported as the n-fold difference relative
to target gene mRNA expression in the calibrator group
(the group of mice immunized with saline) [43].
MicroRNAs expressed by macrophages stimulated in vitro
by docetaxel
The murine macrophage-like cell line RAW264.7 (Invi-
trogen) was cultured in 24-well plastic plates (Greiner)
at a concentration of 2 × 106 cells/ml in High Glucose
DMEM (Hyclone) supplemented with 10% FCS and in
an atmosphere of 90% humidity containing 5% CO2 at
37°C. After the adherent cells were formed, docetaxel so-
lution was added in triplicates to produce a final concen-
tration of 0.8 μg/ml. The cells were harvested after 1
and 3 h incubation for RNA isolation. Expression levels
of microRNAs (miR-181a, miR-155, miR-150, miR-146a
and miR-125b) were detected according to our lab previ-
ously described by Yuan et al. [21]. The primers for
microRNA gene were described in Table 2.
Statistical analyses
Data are expressed as mean ± standard deviations (S.D.)
in addition to HI titers which are expressed as geomet-
rical mean titer (GMT) ± standard deviations (S.D.)
Boniferroni method was used to compare the parameters
between groups by SPSS16.0. P-values of less than 0.05
were considered statistically significant.
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